Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432765 · ClinicalTrials.gov registry record · NA
AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function
A NA study, sponsored by University of Florida.
- Not yet
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT05432765: Clinical Trial NA study, sponsored by University of Florida.
NCT05432765 is a NA study that has not yet begun recruiting, run by University of Florida. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05432765, a NA study, has not yet begun recruiting, sponsored by University of Florida.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The objective of the proposed study it to perform a pilot clinical trial both to establish feasibility of applying a computational, augmented intelligence based approach, Phenotypic Precision Medicine (PPM), to optimizing combination drug therapy and to gather preliminary data to support a larger fully powered multi-center clinical trial. The key rationale for this clinical selection is that we have the technical, biological, and medical expertise in this disease, a wealth of experience in the use of PPM in both in vitro and the clinical setting, and a robust and integrated transplant program with a well-functioning clinical trial infrastructure.
Primary Outcome
Multiple studies have used this outcome because it 1) correlates well with renal function as measured by Creatinine Clearance (CrCl), 2) is a quantitative, continuous, and objective measure, thus needing fewer subjects to show a difference between groups in a small study, and 3) it is less susceptible to acute fluctuations than CrCl and more reflective of chronic injury. Renal allograft IF is a continuous variable that ranges from 0 to 100%.
Interventions
- OTHER Phenotypic Personalized Medicine Dosing
- OTHER Standard of Care Dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-12 |
| Est. Completion | 2031-01-01 |
| Phase | NA |
What is known before NCT05432765 opens enrollment
NCT05432765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Phenotypic Personalized Medicine Dosing is the first listed.
NCT05432765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05432765 about?
NCT05432765 is a clinical study titled "AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function". The objective of the proposed study it to perform a pilot clinical trial both to establish feasibility of applying a computational, augmented intelligence based approach, Phenotypic Precision Medicine (PPM), to optimizing combination drug therapy and to gather preliminary data to support a larger fu...
What is the current status of trial NCT05432765?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2026-12. Estimated completion is 2031-01-01.
What interventions are being tested in trial NCT05432765?
The interventions under investigation include: Phenotypic Personalized Medicine Dosing (OTHER), Standard of Care Dosing (OTHER).
Who is sponsoring clinical trial NCT05432765?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05432765's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia